Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.

Tönnies S, Tönnies M, Kollmeier J, Bauer TT, Förster GJ, Kaiser D, Wernecke KD, Pfannschmidt J.

Lung Cancer. 2016 Mar;93:28-34. doi: 10.1016/j.lungcan.2015.12.008. Epub 2015 Dec 30.

PMID:
26898611
2.

[Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].

Tönnies S, Bauer TT, Misch D, Boch C, Blum T, Bittner RC, Förster GJ, Kollmeier J.

Pneumologie. 2012 Apr;66(4):212-7. doi: 10.1055/s-0032-1308916. Epub 2012 Apr 4. German.

3.

Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer.

Panjideh H, Da Silva Coelho VC, Dernedde J, Bachran C, Förster GJ, Franke J, Fasold P, Fuchs H, Thiel E, Deckert PM.

Int J Oncol. 2008 Apr;32(4):925-30.

PMID:
18360720
4.

Multimodality registration without a dedicated multimodality scanner.

Beattie BJ, Förster GJ, Govantes R, Le CH, Longo VA, Zanzonico PB, Bidaut L, Blasberg RG, Koutcher JA.

Mol Imaging. 2007 Mar-Apr;6(2):108-20.

PMID:
17445505
5.
6.

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P.

Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92. Epub 2004 Jun 3.

PMID:
15175836
7.

Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management.

Kunkel M, Förster GJ, Reichert TE, Jeong JH, Benz P, Bartenstein P, Wagner W, Whiteside TL.

Cancer. 2003 Nov 15;98(10):2257-65.

8.

PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.

Buchholz HG, Herzog H, Förster GJ, Reber H, Nickel O, Rösch F, Bartenstein P.

Eur J Nucl Med Mol Imaging. 2003 May;30(5):716-20. Epub 2003 Feb 26.

PMID:
12605273
9.

Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma.

Kunkel M, Förster GJ, Reichert TE, Kutzner J, Benz P, Bartenstein P, Wagner W.

Oral Oncol. 2003 Feb;39(2):170-7.

PMID:
12509971
10.

SPET/CT image co-registration in the abdomen with a simple and cost-effective tool.

Förster GJ, Laumann C, Nickel O, Kann P, Rieker O, Bartenstein P.

Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):32-9. Epub 2002 Oct 25.

PMID:
12483407
11.

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.

Förster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Mäcke HR, Rösch FR, Herzog HR, Bartenstein PR.

Eur J Nucl Med. 2001 Dec;28(12):1743-50. Epub 2001 Oct 20.

PMID:
11734910
12.

[Therapy monitoring with 2-(18F)-FDG positron emission tomography after neoadjuvant radiation treatment of mouth carcinoma].

Kunkel M, Grötz KA, Förster GJ, Wahlmann U, Benz P, Kutzner J, Rippins G, Wagner W.

Strahlenther Onkol. 2001 Mar;177(3):145-52. German.

PMID:
11285772
13.

Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.

Förster GJ, Krummenauer F, Nickel O, Kahaly GJ.

Cancer Biother Radiopharm. 2000 Oct;15(5):517-25.

PMID:
11155823
14.

[(18F)-2-fluorodeoxyglucose PET. Prospects for secondary prevention of mouth cavity carcinoma].

Kunkel M, Kuffner HD, Reichert TE, Benz P, Förster GJ, Wagner W.

Mund Kiefer Gesichtschir. 2000 Mar;4(2):105-10. German.

PMID:
10851884
15.

Somatostatin receptor scintigraphy in thyroid eye disease.

Kahaly GJ, Förster GJ.

Thyroid. 1998 Jun;8(6):549-52.

PMID:
9669296

Supplemental Content

Loading ...
Support Center